Navigation Links
CRF announces featured clinical trials to be presented at TCT 2010
Date:8/12/2010

NEW YORK, NY August 12, 2010 The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 25 in Washington, DC.

Data from these trials are expected to influence the practice of interventional cardiovascular medicine and have an immediate impact on guidelines and patient care. These featured trials will be highlighted during sessions throughout TCT.

TUESDAY, SEPTEMBER 21, 6:00 PM 7:45 PM

  • SYNTAX Left Main: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Left Main Coronary Artery Disease
  • SYNTAX 3VD: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Triple Vessel Coronary Artery Disease
  • EXECUTIVE: A Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Multivessel Coronary Artery Disease
  • DECLARE-LONG II: A Prospective Randomized Trial of Triple vs. Dual Antiplatelet Therapy to Reduce Restenosis in Long Coronary Lesions Treated with Zotarolimus-Eluting Stents
  • DK-CRUSH-II: A Prospective Randomized Trial of Double Kissing Crush Stenting Compared to Provisional Stenting for Treatment of True Coronary Bifurcation Lesions
  • TRIAS High Risk: A Prospective Randomized Trial of Endothelial Progenitor Cell Capturing Stents Compared to Other Drug-Eluting Stents in Patients with Complex Coronary Artery Disease
  • ROMA: A Prospective Randomized Trial of Rosuvastatin Pretreatment Prior to Percutaneous Coronary Intervention
  • COMPARE-AMI: Two-Year Outcomes from a Prospective, Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with STEMI

WEDNESDAY, SEPTEMBER 22, 6:00 PM 8:00 PM

  • LEADERS: Three-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ESSENCE-DIABETES: A Prospective Randomized Trial of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Diabetes Mellitus and Coronary Artery Disease
  • ZEST: Two-Year Outcomes from a Prospective, Randomized Trial of Sirolimus-Eluting Stents, Paclitaxel-Eluting Stents and Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • APPOSITION II: A Prospective Randomized Trial of Self-Expanding vs. Balloon Expandable Stents in Patients with Acute Myocardial Infarction
  • CLOVIS-2: A Prospective, Randomized, Nested Case-Control Crossover Study of a High vs. Low Clopidogrel Loading Dose in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • PRO-GR: A Prospective, Randomized, Crossover Study of Maintenance High-Dose Clopidogrel vs. Prasugrel in Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • SOURCE TAVI Cohort 2: A Prospective Observational Study of More Than 2,300 Lower Risk and "Valve-in-Valve" Patients Undergoing Transcatheter Aortic Valve Implantation
  • PFO Closure: A Prospective Nonrandomized Propensity-Adjusted Study of PFO Closure Compared to Medical Therapy in Patients with Stroke Presumably Related to PFO

FRIDAY, SEPTEMBER 24, 6:00 PM 8:00 PM

  • LANCELOT CAD: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Coronary Artery Disease
  • MYTHOS: A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy
  • ODS-CAS: A Prospective Randomized Trial of Iso-Osmolar Contrast Compared to Low-Osmolar Contrast to Prevent Contrast Nephropathy in Patients Undergoing Carotid Artery Stenting
  • STEM CELL MOBILIZATION: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Granulocyte Colony Stimulating Factor After Acute Myocardial Infarction in Patients with Low Left Ventricular Ejection Fraction
  • PREVENT-ICARUS: A Prospective, Randomized, Double-Blind Trial of Intracoronary Adenosine to Prevent Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Angioplasty
  • CRYSTAL AMI: A Prospective Randomized Trial of Intracoronary Site-Specific Abciximab Compared to Intravenous Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
  • PEPCAD-CTO: A Prospective Nonrandomized Study of Paclitaxel-Eluting Balloons After Bare Metal Stent Placement in Successfully Recanalized Chronic Total Coronary Occlusions

Media may apply for registration by clicking on: http://www.tctconference.com/press/press-registration-form.html

Details on required press credentials can be found at: http://www.tctconference.com/press/press-credentials-a-guidelines.html

To view the program update, visit: http://www.tctconference.com/pdf/2010program-update.pdf

Receive updates on Twitter: http://twitter.com/TCTConference

View related video content on YouTube: http://www.youtube.com/user/TCTConference


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. Connecture, Inc. Announces Partnership with MedicareCRM
3. Chiquita Announces Support for School Salad Bar Campaign
4. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
5. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
6. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
7. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
10. Sunquest Announces Major Software Updates and Enhancements
11. Data Strategy Announces SurePath Services Offering for EMC Avamar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, and ... with more advantaged communities providing richer opportunities. Recognizing the key role of housing ... improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused policies; ...
(Date:5/24/2016)... Freeport, Grand Bahama (PRWEB) , ... May 24, 2016 , ... ... rapid pace. Such breakthroughs in adult stem cell therapy technology, protocols and patient results ... for this emerging field to become a more accessible standard of care for patients ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed ... data logger for each job, ensuring the best suited solution to meet regulatory ... data loggers at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... appointment of Jonathan (Jon) Otterstatter to its board of directors. Otterstatter ... proven leader in the development of technological innovations that lead to broad-based healthcare ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign ... by more than 1 billion women around the world who do not have access to ... from across the US about their dread of #perioddrama. The (sometimes hilarious) results help shine ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... Gamida Cell, a leader in cellular and ... genetic diseases, announced today it has been awarded a ... Innovation Authority (formerly the Office of the Chief Scientist) ... mission of the Israel Innovation Authority is to encourage ... technology, while stimulating economic growth. The non-dilutive ...
(Date:5/20/2016)... 20, 2016 ReportsnReports.com adds ... Medical Devices of its online business intelligence library. ... the current state of the Titrator industry. The ... like definitions, classifications, Specifications, applications and industry chain ... like Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost ...
Breaking Medicine Technology: